Our main aim was to evaluate the role of caspases’ genes SNPs in Philadelphia-chromosome negative chronic myeloproliferative neoplasms (PN-MPNs) susceptibility. A case-control study in 133 Caucasian Portuguese PN-MPNs patients and 281 matched controls was carried out, studying SNPs in apoptosis related caspases: rs1045485 and rs1035142 (CASP8), rs1052576, rs2308950, rs1132312 and rs1052571 (CASP9), rs2227309 and rs2227310 (CASP7) and rs13006529 (CASP10). After stratification by pathology diagnosis for essential thrombocythemia (ET), female gender or JAK2 positive, there is a significant increased risk for those carrying at least one variant allele for CASP9 (C653T) polymorphism (OR 2.300 CI 95% [1.180–4.484], P = 0.014). However, when considered individually, none of the studied caspases polymorphisms was associated with PN-MPNs risk. Our results do not reveal a significant involvement of caspase genes polymorphisms on the individual susceptibility towards PN-MPNs as a whole. However, for essential thrombocythemia (ET), female gender or JAK2 positive, there is a significant increased risk to those carrying at least one variant allele for CASP9. Although larger studies are required to confirm these results and to provide conclusive evidence of association between these and other caspases variants and PN-MPNs susceptibility, these new data may contribute to a best knowledge of the pathophysiology of these disorders and, in the future, to a more rational and efficient choice of therapeutic strategies to be adopted in PN-MPNs treatment.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Swerdlow CESH, Harris NL et al (2008) WHO classification of Tumours of Haematopoieticand lymphoid tissues., 4 edition (October 27, 2008) ed. World Health Organization, Lyon
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405
James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144–1148
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779–1790
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387–397
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Project CG (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 356:459–468
Tognon R, Nunes NeS, Castro FA (2013) Apoptosis deregulation in myeloproliferative neoplasms. Einstein (Sao Paulo) 11:540–544
Tefferi A, Pardanani A (2015) Myeloproliferative neoplasms: a contemporary review. JAMA Oncol 1:97–105
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391–2405
Rueff J, Rodrigues AS (2016) Cancer drug resistance: a brief overview from a genetic viewpoint. Methods Mol Biol 1395:1–18
Rice KL, Lin X, Wolniak K, Ebert BL, Berkofsky-Fessler W, Buzzai M, Sun Y, Xi C, Elkin P, Levine R, Golub T, Gilliland DG, Crispino JD, Licht JD, Zhang W (2011) Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms. Blood Cancer J 1:e40
Valentino L, Pierre J (2006) JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71:713–721
Bolufer P, Barragan E, Collado M, Cervera J, López JA, Sanz MA (2006) Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression. Leuk Res 30:1471–1491
Delhommeau F, Jeziorowska D, Marzac C, Casadevall N (2010) Molecular aspects of myeloproliferative neoplasms. Int J Hematol 91:165–173
Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, Kusec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR (2010) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115:2891–2900
Kilpivaara O, Levine RL (2008) JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukemia 22:1813–1817
Björkholm M, Hultcrantz M, Derolf Å (2014) Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated? Best Pract Res Clin Haematol 27:141–153
Levine RL (2009) Mechanisms of mutations in myeloproliferative neoplasms. Best Pract Res Clin Haematol 22:489–494
Campregher PV, Santos FP, Perini GF, Hamerschlak N (2012) Molecular biology of Philadelphia-negative myeloproliferative neoplasms. Rev Bras Hematol Hemoter 34:150–155
Goldar S, Khaniani MS, Derakhshan SM, Baradaran B (2015) Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev 16:2129–2144
Kiraz Y, Adan A, Kartal Yandim M, Baran Y (2016) Major apoptotic mechanisms and genes involved in apoptosis. Tumour Biol 37:8471–8486
Zaman S, Wang R, Gandhi V (2014) Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma 55:1980–1992
Green DR, Llambi F (2015) Cell death signaling. Cold Spring Harb Perspect Biol 7
Nunes NS, Tognon R, Moura LG, Kashima S, Covas DT, Santana M, Souto EX, Zanichelli MA, Simões BP, Souza AM, Castro FA (2013) Differential expression of apoptomiRs in myeloproliferative neoplasms. Leuk Lymphoma 54:2047–2051
Tognon R, Gasparotto EP, Leroy JM, Oliveira GL, Neves RP, Carrara ReC, Kashima S, Covas DT, Santana M, Souto EX, Zanichelli MA, Velano CE, Simões BP, Alberto FL, Miyashiro K, de Souza AM, Amarante-Mendes GP, de Castro FA (2011) Differential expression of apoptosis-related genes from death receptor pathway in chronic myeloproliferative diseases. J Clin Pathol 64:75–82
Tognon R, Gasparotto EP, Neves RP, Nunes NS, Ferreira AF, Palma PV, Kashima S, Covas DT, Santana M, Souto EX, Zanichelli MA, Simões BP, de Souza AM, Castro FA (2012) Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in essential thrombocythemia and myelofibrosis. J Hematol Oncol 5:2
Tognon R, Nunes NS, Ambrosio L, Souto EX, Perobelli L, Simões BP, Souza MC, Chauffaille MeL, Attié de Castro F (2016) Apoptosis- and cell cycle-related genes methylation profile in myeloproliferative neoplasms. Leuk Lymphoma 57:1201–1204
Olsson M, Zhivotovsky B (2011) Caspases and cancer. Cell Death Differ 18:1441–1449
Mambet C, Matei L, Necula LG, Diaconu CC (2016) A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms. J Immunoassay Immunochem 37:331–345
Tefferi A, Vardiman JW (2008) Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14–22
Riedl SJ, Salvesen GS (2007) The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 8:405–413
Cho SG, Choi EJ (2002) Apoptotic signaling pathways: caspases and stress-activated protein kinases. J Biochem Mol Biol 35:24–27
Philchenkov A, Zavelevich M, Kroczak TJ, Los M (2004) Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp Oncol 26:82–97
Ng PW, Porter AG, Jänicke RU (1999) Molecular cloning and characterization of two novel pro-apoptotic isoforms of caspase-10. J Biol Chem 274:10301–10308
Oliver L, Vallette FM (2005) The role of caspases in cell death and differentiation. Drug Resist Updat 8:163–170
Petit E, Oliver L, Vallette FM (2009) The mitochondrial outer membrane protein import machinery: a new player in apoptosis? Front Biosci (Landmark Ed) 14:3563–3570
Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626–629
Wang X (2001) The expanding role of mitochondria in apoptosis. Genes Dev 15:2922–2933
Peter ME, Krammer PH (2003) The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10:26–35
Creagh EM, Conroy H, Martin SJ (2003) Caspase-activation pathways in apoptosis and immunity. Immunol Rev 193:10–21
Ding HF, Lin YL, McGill G, Juo P, Zhu H, Blenis J, Yuan J, Fisher DE (2000) Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J Biol Chem 275:38905–38911
Testa U (2004) Apoptotic mechanisms in the control of erythropoiesis. Leukemia 18:1176–1199
Malherbe JA, Fuller KA, Mirzai B, Kavanagh S, So CC, Ip HW, Guo BB, Forsyth C, Howman R, Erber WN (2016) Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasms. J Clin Pathol 69(11):1017-1024
Lan Q, Morton LM, Armstrong B, Hartge P, Menashe I, Zheng T, Purdue MP, Cerhan JR, Zhang Y, Grulich A, Cozen W, Yeager M, Holford TR, Vajdic CM, Davis S, Leaderer B, Kricker A, Schenk M, Zahm SH, Chatterjee N, Chanock SJ, Rothman N, Wang SS (2009) Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. Blood 114:264–267
Kelly JL, Novak AJ, Fredericksen ZS, Liebow M, Ansell SM, Dogan A, Wang AH, Witzig TE, Call TG, Kay NE, Habermann TM, Slager SL, Cerhan JR (2010) Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomark Prev 19:2847–2858
Park JY, Park JM, Jang JS, Choi JE, Kim KM, Cha SI, Kim CH, Kang YM, Lee WK, Kam S, Park RW, Kim IS, Lee JT, Jung TH (2006) Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet 15:1963–1971
Lin J, Lu C, Stewart DJ, Gu J, Huang M, Chang DW, Lippman SM, Wu X (2012) Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk. Carcinogenesis 33:1699–1706
Theodoropoulos GE, Michalopoulos NV, Pantou MP, Kontogianni P, Gazouli M, Karantanos T, Lymperi M, Zografos GC (2012) Caspase 9 promoter polymorphisms confer increased susceptibility to breast cancer. Cancer Genet 205:508–512
Liamarkopoulos E, Gazouli M, Aravantinos G, Tzanakis N, Theodoropoulos G, Rizos S, Nikiteas N (2011) Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer. Gastric Cancer 14:317–321
Florena AM, Tripodo C, Di Bernardo A, Iannitto E, Guarnotta C, Porcasi R, Ingrao S, Abbadessa V, Franco V (2009) Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis. J Clin Pathol 62:331–338
Lindholm Sørensen A, Hasselbalch HC (2015) Smoking and Philadelphia-negative chronic myeloproliferative neoplasms. Eur J Haematol 97(1):63-69
Hasselbalch HC (2015) Smoking as a contributing factor for development of polycythemia vera and related neoplasms. Leuk Res 39:1137–1145
We gratefully acknowledge all patients and controls who generously participated in this study. Our appreciation and thankfulness are extended to Luísa Manso Oliveira and Inês Sousa for expert technical assistance.
This work was supported by funding through project UID/BIM/00009/2013 (Center for Toxicogenomics and Human Health (ToxOmics), from Fundação para a Ciência e Tecnologia (FCT), Portugal.
A BPD grant from FCT to Silva SN (SFRH/BPD/80462/2011) is also acknowledged.
Conflict of Interest
The authors claim no competing financial or intellectual conflicts of interest in the preparation and submission of this manuscript.
About this article
Cite this article
Azevedo, A.P., Silva, S.N., Reichert, A. et al. The Role of Caspase Genes Polymorphisms in Genetic Susceptibility to Philadelphia-Negative Myeloproliferative Neoplasms in a Portuguese Population. Pathol. Oncol. Res. 25, 961–969 (2019). https://doi.org/10.1007/s12253-018-0411-y
- Philadelphia-negative myeloproliferative neoplasms
- Genetic susceptibility
- Caspase genes polymorphisms
- Janus kinase 2